News

Neuroscientists Gary Lewin and James Poulet at the Max Delbrück Center for Molecular Medicine have won highly coveted and competitive ERC Advanced Grants to study pain and the neural mechanisms that underlie temperature perception.

Touch is a fundamental, yet scarcely understood, sense. Now, the team led by Gary Lewin at the Max Delbrück Center has discovered a second ion channel associated with touch perception. Elkin1 could be a target for pain therapy, the team writes in “Science”.

Special receptor cells under the skin enable us to feel pain and touch. But Schwann cells also play a key role in detecting such stimuli, researchers at the Max Delbrück Center report in “Nature Communications.” This discovery opens new avenues for pain therapy.

In neuromuscular diseases, neurons and muscle cells stop communicating properly. Researchers led by Mina Gouti can now model this in 2D in a culture dish. Writing about their findings in “Nature Communications”, they say the new model promises to revolutionize high-throughput drug screening studies.

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.

Simon Haas has been awarded the Lisec-Artz Prize, endowed with €10,000, for his single-cell analysis of communication between stem and immune cells in blood cancer. The University of Bonn Foundation established this prize to honor outstanding early-career cancer researchers.

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable.

Bartter syndrome type 3 is the result of several structural variants in the genome. By using long-read sequencing, Janine Altmüller and her team from the Max Delbrück Center, the BIH and University Hospital Cologne mapped out the rare disease in unprecedented detail. They have now reported their findings in “Genome Medicine.”

Cancer cells are capable of escaping chemotherapy and radiotherapy by activating a signaling pathway that prevents them from dying. Researchers led by Claus Scheidereit at the Max Delbrück Center have now described in Cell Chemical Biology two new compounds that block this escape route.

The Arl8b protein provides new insights into the mechanisms underlying Alzheimer’s disease. It also has the potential to function as a diagnostic marker. The scientists behind this discovery, a team led by Erich Wanker from the Max Delbrück Center, have published their findings in “Genome Medicine”.